The operational and reimbursement challenges that persist at scale, and the strategies that help address them.
Why Large Health Systems Struggle With Lab and Pathology Billing
Category: For Laboratories
Discover the latest news, trends, and best practices in revenue cycle management for lab and diagnostic providers, including coding, billing, and collections.
The Future of Prior Authorization: Automation and Analytics
Master prior auth with smarter workflows and cross-functional alignment—turning a bottleneck into faster patient access and stronger financial performance.
Prior authorization has become one of the most significant operational challenges facing diagnostic laboratories. As testing becomes more complex and payers tighten requirements, the process has evolved into a critical function that directly impacts patient care, provider workflows, and revenue cycle performance.
Uncovering Hidden Revenue Loss: Addressing Underpayments in Pathology
Why missed payments in lab billing often go undetected and how to capture what is owed.
Maximizing Revenue Integrity: A Strategic Edge for Pathology Labs
Taking control of revenue is key to safeguarding margins and strengthening financial results.
The Coverage Gap: Managing Conflicting Payer Policies in Molecular Testing
.png)
Protect lab reimbursement and compliance with strategies to reduce claim denials.
Patient Responsibility: How Labs Can Protect Revenue and Trust
Labs can manage rising patient balances while preserving the confidence and credibility patients rely on.
Short-Term PAMA Relief: What Labs Must Do & Why Long-Term Reform Matters
The clock is ticking on imminent reporting requirements and the urgent need for lasting Medicare rate stability.
On-Demand Webinar—PAMA Relief: Reporting Requirements and the Road to Reform
Congress recently passed short‑term PAMA relief, delaying rate cuts for one year and shifting the next private payer data‑collection period to January–July 2025, with reporting beginning May 2026. While helpful, long‑term reform is still needed, and momentum is growing behind the bipartisan RESULTS Act. In this on‑demand session, ACLA President Susan Van Meter and ACLA General Counsel Joyce Gresko explain what these changes mean for labs, with moderation by Tom Cronin, SVP at Quadax.
PAMA Update: Senate Action and What Comes Next
The Senate has taken a major step forward on PAMA—and laboratories should be paying close attention.
From Revenue to Operations: Our Most‑Watched Webinars for Lab Leaders
.png)
Strengthen revenue performance and reduce risk—watch on-demand now!
